
Alba Ariela Brandes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3594538/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 2005, 352, 987-996.	27.0	17,395
2	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	10.7	6,451
3	Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 709-722.	27.0	2,078
4	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2013, 31, 344-350.	1.6	1,003
5	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. New England Journal of Medicine, 2017, 376, 1027-1037.	27.0	810
6	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology, 2020, 6, 1003.	7.1	805
7	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108.	10.7	800
8	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	10.7	776
9	<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. Journal of Clinical Oncology, 2008, 26, 2192-2197.	1.6	760
10	Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. Journal of Clinical Oncology, 2006, 24, 2715-2722.	1.6	690
11	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	27.0	670
12	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nature Reviews Neurology, 2010, 6, 39-51.	10.1	644
13	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, The, 2009, 374, 1512-1520.	13.7	588
14	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
15	Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034. Journal of Clinical Oncology, 2009, 27, 1268-1274.	1.6	503
16	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, The, 2008, 9, 29-38.	10.7	487
17	Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. Journal of Clinical Oncology, 2006, 24, 2563-2569.	1.6	447
18	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1521-1532.	10.7	396

#	Article	IF	CITATIONS
19	<i>IDH1</i> and <i>IDH2</i> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 2010, 16, 1597-1604.	7.0	364
20	Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With <i>MGMT</i> Promoter Methylation Status. Journal of Clinical Oncology, 2009, 27, 1275-1279.	1.6	311
21	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307
22	Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology, 2003, 21, 2525-2528.	1.6	288
23	Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 2012, 48, 1532-1542.	2.8	248
24	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 110-119.	10.7	238
25	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro-Oncology, 2008, 10, 361-367.	1.2	233
26	<i>MGMT</i> Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2009, 27, 5881-5886.	1.6	232
27	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). British Journal of Cancer, 2006, 95, 1155-1160.	6.4	221
28	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma. Cancer, 2009, 115, 3512-3518.	4.1	207
29	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology, 2016, 18, 1146-1156.	1.2	197
30	Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Journal of Clinical Oncology, 2008, 26, 4659-4665.	1.6	194
31	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. Journal of Clinical Oncology, 2011, 29, 3628-3635.	1.6	182
32	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer, 2007, 96, 1047-1051.	6.4	179
33	Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. Journal of Clinical Oncology, 2006, 24, 4746-4753.	1.6	171
34	A prospective study on glioblastoma in the elderly. Cancer, 2003, 97, 657-662.	4.1	169
35	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. Journal of Thoracic Oncology, 2015, 10, 1437-1443.	1.1	163
36	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. European Journal of Cancer, 2012, 48, 1176-1184.	2.8	161

#	Article	IF	CITATIONS
37	Glioblastoma in adults. Critical Reviews in Oncology/Hematology, 2008, 67, 139-152.	4.4	156
38	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. Neuro-Oncology, 2023, 25, 123-134.	1.2	150
39	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2015, 16, 561-568.	10.7	141
40	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	1.2	137
41	Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment. PLoS ONE, 2014, 9, e103883.	2.5	135
42	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq0 Oncology, The, 2021, 22, 813-823.	0 0 rgBT 10.7	/Overlock 10 132
43	Optimal management of elderly patients with glioblastoma. Cancer Treatment Reviews, 2013, 39, 350-357.	7.7	131
44	Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. British Journal of Cancer, 2004, 90, 353-358.	6.4	130
45	The pathogenesis and treatment of brain metastases: a comprehensive review. Critical Reviews in Oncology/Hematology, 2004, 52, 199-215.	4.4	130
46	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology, 2017, 19, 1542-1552.	1.2	130
47	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget, 2016, 7, 33210-33219.	1.8	128
48	Longâ€ŧerm results of a prospective study on the treatment of medulloblastoma in adults. Cancer, 2007, 110, 2035-2041.	4.1	126
49	Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments. Clinical Cancer Research, 2008, 14, 957-960.	7.0	125
50	Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Journal of Clinical Oncology, 2004, 22, 4779-4786.	1.6	113
51	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. European Journal of Cancer, 2006, 42, 2499-2503.	2.8	111
52	O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-Oncology, 2010, 12, 283-288.	1.2	110
53	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine–DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology. 2017. 35. 343-351.	1.6	110
54	A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer, 2004, 100, 1221-1229.	4.1	105

#	Article	IF	CITATIONS
55	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
56	Chemotherapy in patients with recurrent and progressive central neurocytoma. , 2000, 88, 169-174.		104
57	Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial. Journal of Clinical Oncology, 2007, 25, 5723-5730.	1.6	100
58	First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. Journal of Clinical Oncology, 2004, 22, 1598-1604.	1.6	97
59	Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1533-1542.	10.7	97
60	State-of-the-art treatment of high-grade brain tumors. Seminars in Oncology, 2003, 30, 4-9.	2.2	94
61	The development of platinum compounds and their possible combination. Critical Reviews in Oncology/Hematology, 2006, 60, 59-75.	4.4	94
62	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology, 2009, 64, 769-75.	2.3	89
63	Procarbazine and High-Dose Tamoxifen as a Second-Line Regimen in Recurrent High-Grade Gliomas: A Phase II Study. Journal of Clinical Oncology, 1999, 17, 645-645.	1.6	82
64	The treatment of adults with medulloblastoma: a prospective study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 755-761.	0.8	82
65	Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. Journal of Neuro-Oncology, 2008, 89, 179-185.	2.9	79
66	Fine-needle aspiration cytology of adrenal masses in noncancer patients. Cancer, 2001, 93, 323-329.	4.1	78
67	Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. Annals of Oncology, 2001, 12, 255-258.	1.2	77
68	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	7.7	76
69	A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer, 2005, 104, 143-148.	4.1	75
70	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro-Oncology, 2018, 20, 13-23.	1.2	74
71	Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. British Journal of Cancer, 2006, 94, 785-791.	6.4	73
72	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology, 2009, 11, 737-746.	1.2	71

#	Article	IF	CITATIONS
73	EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. European Journal of Cancer, 2010, 46, 348-354.	2.8	71
74	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-Oncology, 2016, 18, 1304-1312.	1.2	71
75	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e317-e329.	10.7	69
76	The treatment of cranial germ cell tumours. Cancer Treatment Reviews, 2000, 26, 233-242.	7.7	67
77	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-Oncology, 2006, 8, 253-260.	1.2	67
78	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. Oncologist, 2015, 20, 166-175.	3.7	66
79	Prognostic Value of Health-Related Quality-of-Life Data in Predicting Survival in Patients With Anaplastic Oligodendrogliomas, From a Phase III EORTC Brain Cancer Group Study. Journal of Clinical Oncology, 2007, 25, 5731-5737.	1.6	63
80	The Role of Chemotherapy in Recurrent Malignant Gliomas: An Overview. Cancer Investigation, 1996, 14, 551-559.	1.3	62
81	Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treatment Reviews, 2005, 31, 79-89.	7.7	61
82	Role of <i>MGMT</i> Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist, 2017, 22, 432-437.	3.7	61
83	Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treatment Reviews, 2006, 32, 9-27.	7.7	59
84	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro-Oncology, 2012, 14, 1503-1510.	1.2	58
85	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Critical Reviews in Oncology/Hematology, 2009, 71, 165-179.	4.4	56
86	EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncology, The, 2019, 20, e715-e728.	10.7	56
87	Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study. Oncology, 2002, 63, 38-41.	1.9	55
88	Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treatment Reviews, 1999, 25, 3-12.	7.7	54
89	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncology, 2021, 10, CNS72.	3.0	54
90	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	12.3	52

#	Article	IF	CITATIONS
91	Review of the prognostic factors in medulloblastoma of children and adults. Critical Reviews in Oncology/Hematology, 2004, 50, 121-128.	4.4	51
92	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer, 2013, 49, 3477-3485.	2.8	51
93	Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. Current Treatment Options in Oncology, 2016, 17, 49.	3.0	48
94	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. Oncologist, 2019, 24, 521-528.	3.7	47
95	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma Journal of Clinical Oncology, 2016, 34, 2001-2001.	1.6	46
96	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. Oncotarget, 2016, 7, 55169-55180.	1.8	45
97	Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme. Cancer, 1998, 82, 355-361.	4.1	44
98	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology, 2012, 60, 885-894.	2.9	44
99	Cardiovascular Safety of VECF-Targeting Therapies: Current Evidence and Handling Strategies. Oncologist, 2010, 15, 683-694.	3.7	43
100	New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Critical Reviews in Oncology/Hematology, 2015, 94, 348-359.	4.4	43
101	Nitrosoureas in the Management of Malignant Gliomas. Current Neurology and Neuroscience Reports, 2016, 16, 13.	4.2	43
102	The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Research, 2015, 35, 1743-8.	1.1	42
103	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. Oncologist, 2021, 26, 865-878.	3.7	39
104	Glioblastoma in the elderly: Current and future trends. Critical Reviews in Oncology/Hematology, 2006, 60, 256-266.	4.4	38
105	Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC) Tj ETQq1 1 0.	78146814 rg	gB 3 \$Overlock
106	The treatment of elderly patients with high-grade gliomas. Seminars in Oncology, 2003, 30, 58-62.	2.2	37
107	Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. Cancer, 2004, 101, 2079-2085.	4.1	37
108	Phase II Trial with BCNU plus α-Interferon in Patients with Recurrent High-Grade Cliomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 364-367.	1.3	37

#	Article	IF	CITATIONS
109	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. World Neurosurgery, 2018, 112, e342-e347.	1.3	36
110	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 1429-1435.	2.4	35
111	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. Neuro-Oncology, 2019, 21, 1447-1457.	1.2	35
112	Prognostic factors for anaplastic astrocytomas. Journal of Neuro-Oncology, 2007, 81, 295-303.	2.9	33
113	Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?. Critical Reviews in Oncology/Hematology, 2008, 68, 212-221.	4.4	33
114	Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Review of Anticancer Therapy, 2009, 9, 613-619.	2.4	33
115	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. BMC Cancer, 2010, 10, 48.	2.6	33
116	Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Research, 2004, 24, 3221-4.	1.1	33
117	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. International Journal of Molecular Sciences, 2017, 18, 995.	4.1	32
118	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology, 2016, 77, 115-120.	2.3	31
119	Treatment of recurrent high-grade gliomas. Current Opinion in Neurology, 2009, 22, 657-664.	3.6	30
120	Second surgery for recurrent glioblastoma: advantages and pitfalls. Expert Review of Anticancer Therapy, 2013, 13, 583-587.	2.4	29
121	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG) Tj ET	Qq.b 1 0.7	78 43 14 rgBT
122	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients. Journal of Thoracic Oncology, 2014, 9, 733-737.	1.1	28
123	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathologica Communications, 2022, 10, 1.	5.2	28
124	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer, 1990, 65, 2631-2634.	4.1	27
125	Treatment of High-Grade Gliomas in the Elderly. Oncology, 1998, 55, 1-6.	1.9	27
126	Temozolomide in Patients with High Grade Gliomas. Oncology, 2000, 59, 181-186.	1.9	26

#	Article	IF	CITATIONS
127	Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM) Journal of Clinical Oncology, 2013, 31, 2005-2005.	1.6	26
128	Patient outcomes following second surgery for recurrent glioblastoma. Future Oncology, 2016, 12, 1039-1044.	2.4	25
129	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. European Journal of Cancer, 2020, 137, 10-17.	2.8	25
130	Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data Journal of Clinical Oncology, 2015, 33, 2015-2015.	1.6	25
131	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. CNS Drugs, 2017, 31, 675-684.	5.9	24
132	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. Neuro-Oncology Practice, 2014, 1, 166-171.	1.6	23
133	Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. Journal of Neuro-Oncology, 2016, 128, 157-162.	2.9	23
134	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Review of Anticancer Therapy, 2020, 20, 785-795.	2.4	23
135	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	1.6	23
136	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. European Journal of Cancer, 2019, 116, 190-198.	2.8	22
137	Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. Journal of Neuro-Oncology, 1996, 30, 247-55.	2.9	21
138	Current management and prognostic factors for adult ependymoma. Expert Review of Anticancer Therapy, 2002, 2, 537-545.	2.4	21
139	Non-cytotoxic therapies for malignant gliomas. Journal of Neuro-Oncology, 2002, 58, 57-69.	2.9	21
140	Reoperation in Recurrent High-Grade Gliomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 387-390.	1.3	21
141	High-Dose Chemotherapy with Bone Marrow Rescue for High-Grade Gliomas in Adults. Cancer Investigation, 2001, 19, 41-48.	1.3	20
142	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer, 2009, 64, 199-206.	2.0	20
143	Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase Il trials in patients with recurrent glioblastoma. European Journal of Cancer, 2012, 48, 896-903.	2.8	20
144	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	1.6	20

Alba Ariela Brandes

#	Article	IF	CITATIONS
145	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19
146	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. Molecular Diagnosis and Therapy, 2021, 25, 457-473.	3.8	19
147	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) Journal of Clinical Oncology, 2012, 30, 2-2.	1.6	19
148	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. Drugs, 2022, 82, 491-510.	10.9	18
149	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. Journal of Neuro-Oncology, 2017, 135, 245-254.	2.9	17
150	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. Future Oncology, 2018, 14, 1559-1567.	2.4	17
151	Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. Immunotherapy, 2020, 12, 1111-1114.	2.0	17
152	Accuracy of technetium-99m sestamibi scintimammography and X-ray mammography in premenopausal women with suspected breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1776-1780.	6.4	16
153	Medulloblastomas in adults. Current Opinion in Neurology, 2011, 24, 626-632.	3.6	16
154	Advances in malignant glioma drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 739-753.	5.0	16
155	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. Future Oncology, 2014, 10, 1137-1145.	2.4	16
156	Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. Journal of Clinical Pathology, 2015, 68, 859-869.	2.0	16
157	Immunotherapy in head and neck cancer: evidence and perspectives. Immunotherapy, 2017, 9, 1351-1358.	2.0	16
158	Molecular alterations in pancreatic tumors. World Journal of Gastroenterology, 2021, 27, 2710-2726.	3.3	16
159	Glioblastoma: Emerging Treatments and Novel Trial Designs. Cancers, 2021, 13, 3750.	3.7	16
160	Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward. Immunotherapy, 2021, 13, 879-883.	2.0	16
161	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. Diagnostics, 2021, 11, 342.	2.6	15
162	Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management. Journal of Neuro-Oncology, 2000, 47, 85-92.	2.9	14

#	Article	IF	CITATIONS
163	Shedding Light on Adult Medulloblastoma: Current Management and Opportunities for Advances. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e82-e87.	3.8	14
164	Rare Primary Central Nervous System Tumors in Adults: An Overview. Frontiers in Oncology, 2020, 10, 996.	2.8	14
165	Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. Journal of Neuro-Oncology, 2020, 149, 65-71.	2.9	14
166	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma Journal of Clinical Oncology, 2016, 34, 2019-2019.	1.6	14
167	Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio Journal of Clinical Oncology, 2016, 34, 2020-2020.	1.6	14
168	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG) Tj E	ГQq&00 เ	gB 1 4/Overlocl
169	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. Future Oncology, 2020, 16, 1433-1439.	2.4	14
170	Treatment of brain metastases in uncommon tumors. Expert Review of Anticancer Therapy, 2004, 4, 783-793.	2.4	13
171	Predictive markers of immune response in glioblastoma: hopes and facts. Future Oncology, 2020, 16, 1053-1063.	2.4	13
172	Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Review of Anticancer Therapy, 2010, 10, 179-184.	2.4	12
173	Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. Journal of Neuro-Oncology, 2018, 139, 383-388.	2.9	12
174	Cisplatin plus Vindesine versus Cisplatin plus VP16 versus Doxorubicin plus Cytoxan in Non-Small-Cell Carcinoma of the Lung. A Randomized Study. Tumori, 1986, 72, 417-425.	1.1	11
175	Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?. Expert Review of Anticancer Therapy, 2003, 3, 615-620.	2.4	11
176	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. Future Oncology, 2018, 14, 1063-1069.	2.4	11
177	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. Diagnostics, 2021, 11, 1852.	2.6	11
178	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncology, 2013, 9, 1653-1664.	2.4	10
179	Resistance to antiangiogenic therapies. Future Oncology, 2014, 10, 1417-1425.	2.4	10
180	Post progression survival in glioblastoma: where are we?. Journal of Neuro-Oncology, 2015, 121, 399-404.	2.9	10

#	Article	IF	CITATIONS
181	The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Oncology and Therapy, 2018, 6, 105-108.	2.6	10
182	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget, 2017, 8, 55575-55581.	1.8	10
183	Changing boundaries in the treatment of malignant gliomas. Expert Review of Anticancer Therapy, 2001, 1, 357-370.	2.4	9
184	Treatment decisions in elderly patients with glioblastoma. Nature Reviews Neurology, 2012, 8, 664-665.	10.1	9
185	Bevacizumab in recurrent glioblastoma: open issues. Future Oncology, 2015, 11, 2655-2665.	2.4	9
186	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. Neurology, 2019, 92, e2754-e2763.	1.1	9
187	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy, 2021, 13, 419-432.	2.0	9
188	Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression Journal of Clinical Oncology, 2013, 31, 2061-2061.	1.6	9
189	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Review of Anticancer Therapy, 2021, 21, 1333-1353.	2.4	9
190	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. Frontiers in Oncology, 2022, 12, 852950.	2.8	9
191	Primary Brain Tumors in the Elderly Population. Current Treatment Options in Neurology, 2011, 13, 427-435.	1.8	8
192	Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?. Expert Review of Anticancer Therapy, 2011, 11, 657-660.	2.4	8
193	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	1.6	8
194	Unusual nasal and orbital involvement of glioblastoma multiforme: a case report and review of the literature. Journal of Neuro-Oncology, 1998, 36, 179-183.	2.9	7
195	Association between response to primary treatments and <i>MGMT</i> status in glioblastoma. Expert Review of Anticancer Therapy, 2008, 8, 1781-1786.	2.4	7
196	Brain metastases from non-small-cell lung cancer: is there room for improvement?. Expert Review of Anticancer Therapy, 2012, 12, 421-423.	2.4	7
197	Glioneuronal tumors: clinicopathological findings and treatment options. Future Neurology, 2020, 15, .	0.5	7
198	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. European Journal of Cancer, 2021, 145, 171-178.	2.8	7

#	Article	IF	CITATIONS
199	Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion byÂFISH. Journal of Molecular Diagnostics, 2021, 23, 1185-1194.	2.8	7
	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant		

and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061,) Tj ETQq01060 rgBT (Overlock 1

201	Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma Journal of Clinical Oncology, 2015, 33, 2006-2006.	1.6	7
202	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neuro-Oncology Practice, 2022, 9, 310-316.	1.6	7
203	Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology, 2022, 24, 2159-2169.	1.2	7
204	Tumor-Associated Microenvironment of Adult Gliomas: A Review. Frontiers in Oncology, 0, 12, .	2.8	7
205	New Agents and New End Points for Recurrent Gliomas. Journal of Clinical Oncology, 2011, 29, e245-e246.	1.6	6
206	The role of systemic and targeted therapies in brain metastases. Expert Review of Anticancer Therapy, 2014, 14, 93-103.	2.4	6
207	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. Diagnostics, 2020, 10, 265.	2.6	6
208	IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. Pathology Research and Practice, 2021, 221, 153445.	2.3	6
209	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) Journal of Clinical Oncology, 2012, 30, 2-2.	1.6	6
210	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. Cancers, 2022, 14, 333.	3.7	6
211	Bevacizumab in brain tumors: ready for primetime?. Future Oncology, 2009, 5, 1183-1184.	2.4	5
212	Genetic variation in pediatric and adult brain tumors. Nature Reviews Neurology, 2010, 6, 653-654.	10.1	5
213	The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials. CNS Oncology, 2015, 4, 117-119.	3.0	5
214	Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. Future Oncology, 2019, 15, 2595-2601.	2.4	5
215	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. Neuro-Oncology Practice, 2020, 7, 668-675.	1.6	5
216	How to face cancer treatment in the COVID-19 era. Expert Review of Anticancer Therapy, 2020, 20, 429-432.	2.4	5

#	Article	IF	CITATIONS
217	The clinical and prognostic role of ALK in glioblastoma. Pathology Research and Practice, 2021, 221, 153447.	2.3	5
218	A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma Journal of Clinical Oncology, 2015, 33, 2014-2014.	1.6	5
219	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. Immunotherapy, 2022, 14, 169-172.	2.0	5
220	Novel therapeutics in adult malignant brain gliomas. Expert Opinion on Investigational Drugs, 2005, 14, 643-658.	4.1	4
221	Distinct MRI pattern of "pseudoresponse―in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. Clinical Case Reports (discontinued), 2021, 9, e04604.	0.5	4
222	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. Expert Review of Anticancer Therapy, 2021, 21, 1265-1272.	2.4	4
223	Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. Oncology, 2012, 26, 1083-91.	0.5	4
224	Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies. Expert Review of Anticancer Therapy, 2003, 3, 167-178.	2.4	3
225	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. Expert Review of Anticancer Therapy, 2011, 11, 1713-1717.	2.4	3
226	Cytologically confirmed splenic metastases in breast cancer. Future Oncology, 2012, 8, 1495-1500.	2.4	3
227	The burden of oncology promises not kept in glioblastoma. Future Neurology, 2018, 13, 1-4.	0.5	3
228	Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?. Child's Nervous System, 2019, 35, 2279-2287.	1.1	3
229	Postsurgical Approaches in Lowâ€Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. Oncologist, 2019, 24, 664-670.	3.7	3
230	Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714) Journal of Clinical Oncology, 2012, 30, 7550-7550.	1.6	3
231	Immunotherapy in elderly patients: should we stay or should we go?. Future Oncology, 2020, 16, 973-974.	2.4	3
232	Burnout in medical oncology during the COVID-19 pandemic. Expert Review of Anticancer Therapy, 2021, 21, 351-353.	2.4	3
233	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. Immunotherapy, 0, , .	2.0	3
234	New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. Expert Review of Anticancer Therapy, 2006, 6, 1129-1131.	2.4	2

Alba Ariela Brandes

#	Article	IF	CITATIONS
235	Adjuvant temozolomide: how long and how much?. Expert Review of Anticancer Therapy, 2008, 8, 663-665.	2.4	2
236	Gangliogliomas: recent advances in classification and treatment. Future Neurology, 2010, 5, 557-568.	0.5	2
237	The metastatic process: a kaleidoscope of concepts. Future Oncology, 2014, 10, 697-698.	2.4	2
238	Immune-checkpoint inhibitors in pituitary malignancies. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	1.4	2
239	Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients. Neurosurgery, 2021, 89, 1042-1051.	1.1	2
240	Anaplastic gliomas at first recurrence: Outcome analysis Journal of Clinical Oncology, 2012, 30, 2061-2061.	1.6	2
241	Introduction: future trends in the treatment of brain tumors. Seminars in Oncology, 2003, 30, 1-3.	2.2	1
242	Adding temozolomide to radiotherapy prolongs survival in people with glioblastoma. Cancer Treatment Reviews, 2005, 31, 577-581.	7.7	1
243	Trastuzumab in CNS progressive metastatic breast cancer. Future Oncology, 2007, 3, 367-369.	2.4	1
244	Adjuvant therapy in glioblastomas: false steps and real advances. Expert Review of Anticancer Therapy, 2007, 7, 607-608.	2.4	1
245	The role of gender in glioblastoma: does it matter?. Future Neurology, 2016, 11, 197-199.	0.5	1
246	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. Tumori, 2021, , 030089162110172.	1.1	1
247	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. Clinical Drug Investigation, 2021, 41, 757-773.	2.2	1
248	Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study Journal of Clinical Oncology, 2015, 33, 2047-2047.	1.6	1
249	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. Neuro-Oncology Advances, 2020, 2, vdaa147.	0.7	1
250	Challenges and progress in the treatment of adult medulloblastomas. Future Oncology, 2007, 3, 115-117.	2.4	0
251	CNS Oncology: reflecting a rapidly changing landscape. CNS Oncology, 2012, 1, 1-2.	3.0	0
252	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. European Journal of Cancer, Supplement, 2012, 10, 20-26.	2.2	0

#	Article	IF	CITATIONS
253	Metastatic process: the seed and the soil from bench to bedside. Future Oncology, 2013, 9, 1597-1598.	2.4	0
254	NI-26 * COMPARATIVE ANALYSIS OF THE RANO AND MACDONAD'S CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE Neuro-Oncology, 2014, 16, v143-v144.	1.2	0
255	ACTR-01. THE ROLE OF CLINICAL CHARACTERISTICS IN LOW GRADE GLIOMAS PATIENTS IN THE ERA OF MOLECULAR BIOMARKERS: AÂSTUDY FROM GRUPPO ITALIANO COOPERATIVO DI NEURO-ONCOLOGIA (GICNO). Neuro-Oncology, 2016, 18, vi1-vi1.	1.2	0
256	Medulloblastomas. , 2011, , 415-433.		0
257	Natural history of glioblastoma in the modern era: Longitudinal results from a large prospective Italian register Journal of Clinical Oncology, 2012, 30, 2057-2057.	1.6	0
258	Final results from a large prospective Italian population study on glioblastoma and correlations with <i>MGMT</i> status: The Project of Emilia-Romagna Region in Neuro-oncology (PERNO) Journal of Clinical Oncology, 2013, 31, 2048-2048.	1.6	0
259	A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology;) Tj ETQq1 1 0. methylation status in the elderly population Journal of Clinical Oncology, 2013, 31, 2021-2021.	784314 rg 1.6	gBT /Overlo 0
260	Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients Journal of Clinical Oncology, 2015, 33, 8079-8079.	1.6	0
261	The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study Journal of Clinical Oncology, 2016, 34, 2032-2032.	1.6	0
262	Chemotherapy in brain metastases of lung and breast cancer. Therapy: Open Access in Clinical Medicine, 2004, 1, 101-110.	0.2	0
263	Temozolomide in glioblastoma multiforme of the elderly. Tumori, 2002, 88, S69-70.	1.1	0